Troglitazone

In the treatment pathway for metabolic-related diseases, thiazolidinedione insulin sensitizers were once an important direction for the R&D of type 2 diabetes drugs. As the first marketed drug in this category, troglitazone activates peroxisome proliferator-activated receptor γ (PPARγ), regulates the transcription of insulin response genes, improves the insulin sensitivity of peripheral tissues, and reduces blood glucose and glycosylated hemoglobin levels. It was once used as monotherapy or combination therapy for patients with type 2 diabetes whose condition is poorly controlled by diet and exercise. However, severe hepatotoxicity risks were discovered in subsequent clinical applications, and it has now been withdrawn from the market globally. Relevant research is mainly concentrated in the fields of drug toxicological mechanism analysis and reference for the optimization of similar drugs.

As troglitazone has been discontinued for clinical use, there is currently no publicly verifiable commercial market size and growth data. On the market side, only a small amount of experimental-grade samples for toxicological research and impurity control analysis are supplied. The relevant supply is dominated by customized laboratory production, and there is no large-scale market competition pattern.

The original developer of troglitazone is Sankyo Co., Ltd. of Japan, with the original brand name Rezulin. Its U.S. compound patent expired in 2004; the main dosage form of the original product is oral tablet, with specifications including 200mg and 400mg. It was once included in the FDA Reference Listed Drug Catalog, and was later withdrawn from the market due to safety issues. Currently, there is no registered DMF number for troglitazone API in China, and no domestically approved troglitazone preparation products are on the market. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of troglitazone impurity reference standards, which fully meet the reference standard needs of experimental scenarios such as drug toxicology research and quality analysis. Most products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. They fully comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and provide stable and reliable reference standard supply support for scientific research and testing scenarios.